TY  - JOUR
UR  - https://doi.org/10.1016/j.jhepr.2024.101200
PB  - ELSEVIER
N2  - Background & Aims: Quantifying alcohol intake is crucial for subclassifying participants with steatotic liver disease (SLD) and interpreting clinical trials of alcohol-related liver disease (ALD) and metabolic and alcohol-related liver disease (MetALD). However, the accuracy of self-reported alcohol intake is considered imprecise. We compared the diagnostic and prognostic utility of self-reported alcohol intake with blood-based biomarkers of alcohol intake: phosphatidylethanol (PEth) and carbohydrate-deficient transferrin (CDT). Methods: We studied 192 participants from two randomized controlled trials on MetALD and ALD, all with current or former excessive alcohol intake (?24/36 [?/?] grams daily for at least 1 year) and biopsy-proven liver disease. We assessed self-reported alcohol intake, PEth, and CDT at four time points. We collected follow-up data on hepatic decompensation and death manually through electronic medical records. Results: Most participants were male (n = 161, 84%) with a mean age of 59 (SD 9) years and 73 participants reported 1-week abstinence before inclusion; the remaining reported a median alcohol intake of 43 g/day. Median PEth was 0.5 ?mol/L (IQR: 0.0?1.3) and %CDT = 1.9 (IQR: 1.6?2.3). Of 32 patients reporting at least 6 months of abstinence; 27 (84%) was confirmed by PEth <0.05 ?mol/L. Self-reported alcohol intake correlated well with PEth (r = 0.617) and moderately with CDT (r = 0.316). Self-reported alcohol intake, PEth, and CDT all predicted hepatic decompensation and death. However, PEth showed the highest prediction, surpassing self-reported alcohol intake (Harrel's C, PEth = 0.80 vs. self-reported = 0.68, p = 0.026). Conclusions: Self-reported abstinence can be considered reliable in clinical trials. However, PEth is superior in predicting hepatic decompensation and death in patients with MetALD and ALD. Impact and implications: An accurate quantification of alcohol intake is crucial in the clinical phenotyping of patients with steatotic liver disease and when designing clinical trials. This study found self-reported abstinence to be reliable but phosphatidylethanol was a more accurate prognostic biomarker of hepatic decompensation and death in a clinical trial setting. Findings may inform the design of future trials in patients with steatotic liver disease.
ID  - discovery10204498
A1  - Hansen, Emil Deleuran
A1  - Torp, Nikolaj
A1  - Johansen, Stine
A1  - Hansen, Johanne Kragh
A1  - Bergmann, Marianne Lerbaek
A1  - Hansen, Camilla Dalby
A1  - Detlefsen, Sonke
A1  - Andersen, Peter
A1  - Villesen, Ida
A1  - Bech, Katrine
A1  - Thorhauge, Katrine
A1  - Jensen, Gitte Hedegaard
A1  - Lindvig, Katrine Prier
A1  - Hansen, Torben
A1  - Tsochatzis, Emmanuel A
A1  - Trebicka, Jonel
A1  - Thiele, Maja
A1  - Krag, Aleksander
A1  - Israelsen, Mads
JF  - JHEP Reports
Y1  - 2025/01//
AV  - public
VL  - 7
EP  - 9
TI  - Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake
IS  - 1
N1  - © 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL) under a Creative Commons license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ER  -